Clinical Data Analysis, Should compared with Normal tissue?
Just curious about how to compare RNA-seq data from clinical patient.
I saw an old tutorial post, which transform all data to Z-score,
Just curious, based on that conversion, we are looking at def expression genes with normal tissue, not the gene with high expression or low expression within the tumor sample.
Is it a standard that all the data should be normalized with their control sample?
Thanks
1 answer
Log in to answer this question.
More posts like this
-
high throughput drug screening
written by Ahmed.waraky •
-
R Gene Expression Survival Analysis with Only Tumor Expression Data
written by menon_ankita •
-
survival analysis based on gene expression for one gene only
written by majd.abdulghani •
-
Expression values for normal tissues
written by rizoic
-
For cancer classification, can I use normal tissue sample of patients?
written by miniymay101 •
-
How does cBioPortal normalize data
written by Wenhu_Cao
-
why are RNA-seq fkpm of TCGA PAN-cancer normal and primary tumor are the same
written by zany1983 •
-
calculation of Z-score from Isoform expression data
written by sumithra.das •
-
Differential expression gene list from TCGA level 3 RNASeq V2 datasets downloaded from UCSC Cancer …
written by zeeniajagga •
-
TCGA survival analysis with z-scores all samples altered
written by TriS
It's very rare to compare RNA-seq data using Z-scores for the purposes of differential expression. Typically you'd use DESeq2, edgeR or voom (or one of a number of other similar tools), for which the input is raw read counts